We propose an immunoglobulin preparation with significantly higher anti-inflammatory effects compared to conventional immunoglobulin preparations, along with its manufacturing method.
Intravenous immunoglobulin (IVIG) preparations have recently seen an increasing demand as treatments for autoimmune diseases such as Kawasaki disease. However, there are concerns about future supply issues since the raw materials are derived from plasma components obtained from many healthy donors. The new immunoglobulin preparation introduced here exhibits approximately ten times the anti-inflammatory effect compared to conventional products, which could significantly reduce the amount of raw materials used and also considerably lower costs. [Features] - A manufacturing method for galactosyl non-fucosylated (G2) serum IgG has been established. - (G2) IgG is a natural component found in the blood of healthy individuals, and by binding to the FcγIIIa receptor on natural killer (NK) cells, it suppresses immune overreaction and inflammation. - Its efficacy has been confirmed through experiments conducted on mice.
Inquire About This Product
basic information
Related patents: JP 2021-42195 PCT/JP2021/008404
Price range
Delivery Time
Applications/Examples of results
Kawasaki disease, idiopathic thrombocytopenic purpura, Guillain-Barré syndrome, multiple sclerosis, chronic rheumatoid arthritis, systemic lupus erythematosus, pemphigus, pemphigoid, myasthenia gravis, ANCA-associated vasculitis, chronic inflammatory demyelinating polyneuropathy, autoimmune neutropenia, autoimmune hemolytic anemia, autoimmune acquired factor VIII deficiency, Stiff Person syndrome, multifocal neuropathy, Behçet's disease, ulcerative colitis, Crohn's disease, Reiter's arthritis, polymyositis, dermatomyositis, localized scleroderma, systemic scleroderma, Sjögren's syndrome, anti-glomerular basement membrane nephritis, primary sclerosing cholangitis, primary antiphospholipid syndrome, toxic epidermal necrolysis, graft-versus-host disease, sepsis, etc.
catalog（2）
Download All Catalogs
Company information
Yamaguchi TLO Co., Ltd. is a TLO approved by the Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Economy, Trade and Industry based on the Act on the Promotion of Technology Transfer from Universities, established in November 1999 with investments from 50 faculty members of Yamaguchi University (capital of 4 million yen) before incorporation. It is a liaison-type technology transfer organization that bridges people. We return the research results from the university to society in the form of technology transfer and other means. Additionally, we are actively recruiting member companies to prioritize the disclosure of invention information and contribute to the development of the local economy through these efforts.
![[Research Material] Global Market for Isorhinal Sulfate 2-Sulfatase](https://image.mono.ipros.com/public/product/image/629/2001456799/IPROS47738922239902494504.jpeg?w=280&h=280)
